EUVIMEDEUVIMED entdecken
Open Access

Design and Rationale the SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study

Frederick L Ruberg iD, William S Blaner, Codruta Chiuzan iD, Lawreen H Connors, Andrew J Einstein iD, Denise Fine, Stephen Helmke, Damian Kurian, Shivda Pandey, Farbod Raiszadeh, Carlos Rodriguez, Natalia Sabogal und 7 weitere

Journal of the American Heart Association · 2023

DOI: 10.1161/jaha.122.028534 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Frederick L Ruberg und 18 weiteren Autor:innen. Beteiligte Einrichtung: Section of Cardiovascular Medicine, Department of Medicine Boston University Chobanian & Avedisian School of Medicine Boston Medical Center Boston MA…. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies, Heart Failure. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an important cause of heart failure in older individuals. Misfolding and deposition of transthyretin or prealbumin protein causes ATTR‐CM in the context of a normal (wild‐type) or variant TTR sequence. Variant ATTR‐CM is most commonly caused by the substitution of valine for isoleucine at position 122 in transthyretin (Val122Ile or pV142I, almost exclusively observed in individuals of West African ancestry), demonstrated in 3.4% of self‐identified Black individuals in the United States with an estimated 1.5 million carriers. Despite the large number of known pV142I carriers, the proportion of older Black patients with heart failure attributable to ATTR‐CM remains unknown.

Methods

To address this knowledge gap, the SCAN‐MP (Screening for Cardiac Amyloidosis with Nuclear Imaging in Minority Populations) study was funded by the National Institutes of Health/National Heart, Lung, and Blood Institute (R01HL139671) to enroll a targeted population of self‐identified, community‐dwelling Black or Caribbean Hispanic patients (many of whom are of West African ancestry) >60 years of age with heart failure and identify ATTR‐CM by noninvasive nuclear imaging. The principal objective of SCAN‐MP is to determine the prevalence of ATTR‐CM in this population. Secondary objectives will explore TTR genotype, demographics, progression of variant versus wild‐type ATTR‐CM, and biochemical mechanisms of transthyretin amyloid fibril formation.

Conclusions

The SCAN‐MP study is the largest, prospective study of cardiac amyloidosis in Black and Hispanic individuals. Both wild‐type and variant ATTR‐CM are now treatable with the US Food and Drug–approved drug tafamidis. The insights gained from SCAN‐MP are likely to improve those at risk for or afflicted with ATTR‐CM. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03812172.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialCardiomyopathiesHeart FailureHumansAgedPrealbuminProspective StudiesHealth Disparate Minority and Vulnerable Populations

Stichwörter der Autor:innen

amyloidosiscardiomyopathydisparitiesprecision medicine

Substanzen

Prealbumin

Autor:innen und Institutionen

  • Section of Cardiovascular Medicine, Department of Medicine Boston University Chobanian & Avedisian School of Medicine Boston Medical Center Boston MA USA.
  • Amyloidosis Center Boston University Chobanian & Avedisian School of Medicine Boston MA USA.
  • Department of Medicine Vagelos College of Physicians and Surgeons Columbia University Irving Medical Center New York NY.
  • Feinstein Institute for Medical Research, Northwell Health New York NY.
  • Department of Pathology and Laboratory Medicine Boston University Chobanian & Avedisian School of Medicine Boston Medical Center Boston MA USA.
  • Seymour, Paul, and Gloria Milstein Division of Cardiology Department of Medicine Columbia University Irving Medical Center New York NY.

ORCID-Profile: Frederick L Ruberg, Codruta Chiuzan, Andrew J Einstein, Wendy K Chung, Edward J Miller, Jeffery W Kelly, Mathew S Maurer

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Ruberg, F. L., Blaner, W. S., Chiuzan, C., Connors, L. H., Einstein, A. J., Fine, D., Helmke, S., Kurian, D., Pandey, S., Raiszadeh, F., Rodriguez, C., Sabogal, N., Teruya, S., Winburn, M., Chung, W. K., Cohn, E., Miller, E. J., Kelly, J. W., & Maurer, M. S. (2023). Design and Rationale the SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.122.028534

Vancouver

Ruberg FL, Blaner WS, Chiuzan C, Connors LH, Einstein AJ, Fine D, et al. Design and Rationale the SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. Journal of the American Heart Association. 2023. doi:10.1161/jaha.122.028534

BibTeX
@article{Ruberg2023,
  author = {Ruberg, Frederick L and Blaner, William S and Chiuzan, Codruta and Connors, Lawreen H and Einstein, Andrew J and Fine, Denise and Helmke, Stephen and Kurian, Damian and Pandey, Shivda and Raiszadeh, Farbod and Rodriguez, Carlos and Sabogal, Natalia and Teruya, Sergio and Winburn, Morgan and Chung, Wendy K and Cohn, Elizabeth and Miller, Edward J and Kelly, Jeffery W and Maurer, Mathew S},
  title = {Design and Rationale the SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study},
  journal = {Journal of the American Heart Association},
  year = {2023},
  doi = {10.1161/jaha.122.028534}
}
Kostenlos starten →